SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC July 15, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as 1L Treatment for Nasopharyngeal Carcinoma July 15, 2025
BRAFTOVI® (encorafenib) combo approved in China for treating previously-treated BRAFV600E-mutant metastatic CRC July 15, 2025
Lisaftoclax (APG-2575) approved by China’s NMPA for the treatment of adult 2L+ CLL/SLL patients July 15, 2025
Imfinzi approved in the EU for muscle-invasive bladder cancer based on data from NIAGARA Ph 3 trial July 8, 2025
ZEGFROVY (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for NSCLC with EGFR Ex 20 Insertion Mutations July 8, 2025
EC granted conditional marketing authorization for Ziihera® (zanidatamab) monotherapy for unresectable locally advanced or metastatic previously treated HER2-positive biliary tract cancer July 8, 2025
MHRA approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive NMIBC July 8, 2025
Lynozyfic (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of R/R Multiple Myeloma July 8, 2025
NMPA approves ORPATHYS + TAGRISSO combo in China for the Treatment of Lung Cancer Patients with MET Amplification After Progression on 1L EGFR Inhibitor July 1, 2025
FDA Approves Monjuvi (tafasitamab-cxix), Rituximab, and Lenalidomide Combination for Patients with R/R Follicular Lymphoma June 24, 2025
US FDA Approves ZUSDURI™ (mitomycin) for Intravesical Solution for Recurrent Low-Grade Intermediate-Risk NMIBC June 17, 2025
CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the 1L Treatment of Gastric/GEJ Cancer June 17, 2025
FDA Approves KEYTRUDA for PD-L1+ Resectable Locally Advanced SCCHN as Neoadjuvant and Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent June 17, 2025
Fixed-duration Calquence-based regimens approved in EU for 1L CLL patients based on AMPLIFY Ph 3 trial results June 11, 2025
EC Approves ADCETRIS® (brentuximab vedotin) for the Treatment of 1L Patients with Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD June 10, 2025
European Commission Approves SC Formulation of Opdivo Across Multiple Solid Tumor Indications June 3, 2025
NMPA Approves Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer June 3, 2025
NMPA approves Minjuvi (Tafasitamab) + Lenalidomide for the treatment of Adult Patients with R/R DLBCL in China May 27, 2025
EU approved Neoadjuvant Opdivo + Chemo Followed by Adjuvant Opdivo for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% based on CheckMate-77T trial results May 21, 2025
FDA Approves EMRELIS (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced NSCLC With High c-Met Protein Overexpression May 21, 2025
